… -mutant NSCLC, the treatment decision should ideally be based on assessing differences
in effectiveness of each EGFR TKI against the trade-off of differences in treatment-related …

… of glucocorticoids may reduce the efficacy of EGFR-TKIs in such patients. … efficacy of three
EGFR-TKIs as first-line treatment in patients with advanced NSCLC harboring EGFR mutations…

… the cost-effectiveness of an EGFR mutation testing strategy … with gefitinib for patients harbouring
an EGFR mutation in … the EGFR mutation status, and CTX for those patients with EGFR-wt…

… EGFR mutations in our study may not have been large enough to confirm the efficacy of
afatinib in these patients. A larger sample of patients with uncommon EGFR mutations are …

… EGFR mutations [Citation11]. This review summarizes gefitinib’s pharmacological property,
clinical efficacy, … supports the efficacy and tolerability of gefitinib in treating EGFR mutation-…

… its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in …
patients with wild-type EGFR or unknown EGFR mutation status had a shorter progression-free …

… Citation1 In the last decade, the discovery of epidermal growth factor receptor (EGFR) and
the remarkable efficacy of tyrosine kinase inhibitors (TKIs) in patients with EGFR mutations …

… of EGFR-TKIs with chemotherapy showed a better efficacy and acceptable side effects
comparing with EGFR-TKIs alone in advanced NSCLCs with activating EGFR mutation and BIM …

… with gefitinib in patients with NSCLC and EGFR mutations … the efficacy and safety of dacomitinib
versus gefitinib as first-… metastatic NSCLC with EGFR activating mutations. The primary …

… gefitinib with erlotinib and found no difference in efficacy and … first-line EGFR-targeted TKIs
in patients with EGFR mutation-… We hypothesise that the efficacy benefits with afatinib reflect …